Cord Blood News Volume 6.11 | Mar 27 2014

Umbilical Cord Mesenchymal Stem Cell Transplantation in Active and Refractory Systemic Lupus Erythematosus: A Multicenter Clinical Study
Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) have shown a good safety profile and therapeutic effect in severe and refractory systemic lupus erythematosus (SLE) in the authors’ single-center pilot study. The present multicenter clinical trial was undertaken to assess the safety and efficacy of allogenic UC-MSC transplantation in active and refractory SLE patients. [Arthritis Res Ther] Abstract | Full Article

Neurotherapeutic Effect of Cord Blood Derived CD45+ Hematopoietic Cells in Mice after Traumatic Brain Injury
Cell therapy by human umbilical cord blood (HUCB) has shown promising results in animal models of traumatic brain injury (TBI) and is under evaluation in clinical trials. HUCB contains different cell populations, but to date only mesenchymal stem cells have been evaluated for therapy of TBI. The authors present the neurotherapeutic effect, as evaluated by neurological score, using a single dose of HUCB-derived mononuclear cells upon intravenous administration one day post-trauma in a mouse model of closed head injury. [J Neurotrauma] Abstract

The Anti-Oxidative Role of Micro-Vesicles Derived from Human Wharton-Jelly Mesenchymal Stromal Cells through NOX2/gp91(phox) Suppression in Alleviating Renal Ischemia-Reperfusion Injury in Rats
Scientists hypothesized that micro-vesicles derived from human Wharton Jelly mesenchymal stromal cells could protect kidney against ischemia/reperfusion injury through mitigating oxidative stress. [PLoS One] Full Article

Comparison of Articular Cartilage Repair with Different Hydrogel-Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Composites in a Rat Model
The authors aimed to explore the feasibility and efficacy of articular cartilage repair using composites of human umbilical cord blood derived mesenchymal stem cells and four different hydrogels in a rat model. [Stem Cell Res Ther] Abstract | Full Article

Microvesicles Derived from Human Wharton’s Jelly Mesenchymal Stromal Cells Ameliorate Renal Ischemia-Reperfusion Injury in Rats by Suppressing CX3CL1
Scientists focused on the therapeutic effects of human Wharton-Jelly mesenchymal stromal cell derived microvesicles in renal ischemia-reperfusion injury and its potential mechanisms. [Stem Cell Res Ther]
Abstract | Full Article

Characterization and In-Vitro Differentiation Potency of Early-Passage Canine Amnion- and Umbilical Cord-Derived Mesenchymal Stem Cells as Related to Gestational Age
The authors cytogenetically and molecularly characterized and followed the in vitro proliferation and differentiation potential of early-passage canine amniotic membrane mesenchymal stem cells (MSCs) and umbilical cord matrix MSCs isolated from fetuses at early (35-40 days) and late (45-55 days) gestational ages. [Mol Reprod Dev] Abstract

Low Immunogenicity of Allogeneic Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells In Vitro and In Vivo
Researchers showed that allogeneic human umbilical cord blood derived-mesenchymal stem cells (hUCB-MSCs) maintained low immunogenicity even after immune challenge in vitro. To confirm these properties in vivo, a humanized mouse model was established by injecting isolated hUCB-derived CD34+ cells intravenously into immunocompromised NOD/SCID IL2γnull mice. [Biochem Biophys Res Commun] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Cord Blood Registry’s Newborn Possibilities Program
For families that have been identified with a qualifying medical condition currently treatable with a cord blood stem cell transplant or a high-risk pregnancy, the Newborn Possibilities Program provides no-cost newborn stem cell processing and five years of storage. [PR Newswire Association LLC] Press Release

Cesca Therapeutics Submits Pre-IDE Information Package to FDA for Surgwerks(TM) CLI therapy System
Cesca Therapeutics, Inc., an autologous cell based regenerative medicine company, announced it has submitted a pre-IDE (Investigational Device Exemption) information package to the U. S. Food and Drug Administration (FDA) for the use of the SurgWerks™ CLI Therapy designed to treat no option patients with late stage critical limb ischemia (CLI). [GlobeNewswire, Inc.] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Postdoctoral Position – Hematopoietic Stem Cell & Neutrophil Cell Polarity (Cincinnati Children’s Hospital Medical Center)

Cell Therapy Lab Technologist II (Fred Hutchinson Cancer Research Center)

Postdoctoral Fellow – Mammalian Hematopoietic and Erythroid Development (The Icahn School of Medicine at Mount Sinai)

Postdoctoral Position – Human Stem Cell Biology and Hematopoiesis (Johns Hopkins University School of Medicine)

Director of GMP/GLP Quality Operations (University of Pennsylvania, Perelman School of Medicine)

Director – Clinical Immunogenetics Laboratory (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Hematopoietic Stem Cell Biology (St. Jude Children’s Research Hospital)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.